According to the clinical guideline on systemic therapy for advanced HCC, the combination of immune checkpoint inhibitor (ICI) anti-programmed cell death-ligand-1 (PD-L1) antibody atezolizumab and anti-vascular endothelial growth factor antibody bevacizumab (Atezo/Bev) is currently recommended as a first-line treatment in patients with preserved liver function,3 as well as the ICI combination treatment that contains anti-CTLA-4 antibody tremelimumab and anti-PD-L1 antibody durvalmab (Single Tremelimumab Regular Interval Durvalmab regimen).4, 5, 6. Here, VEGFA is linked to hepatocellular carcinoma.